SCHEMBL24285854

SCHEMBL24285854

Nc1nc2ccc(-c3ccc4[nH]ccc4c3)cn2c1C(=O)[C@@H]1C[C@@H]1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LRRK2 Q5S007 6/20 0.42
▸ ABL1 P00519 8/20 0.37
▸ HDAC2 Q92769 1/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ EGFR P00533 1/20 0.36
▸ HCK P08631 1/20 0.36
▸ SRC P12931 1/20 0.36
▸ KDR P35968 1/20 0.36
▸ PIK3CA P42336 1/20 0.36
▸ PIK3CB P42338 1/20 0.36
▸ MTOR P42345 1/20 0.36
▸ PIK3CG P48736 1/20 0.36
▸ EPHB4 P54760 1/20 0.36
▸ PRKDC P78527 1/20 0.36
▸ PI4KB Q9UBF8 1/20 0.36
▸ PI4K2A Q9BTU6 1/20 0.36
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24286022 1.00 LRRK2 (0.42) LRRK2ABL1HDAC2GSK3AGSK3B
SCHEMBL29537329 1.00 LRRK2 (0.42) LRRK2ABL1HDAC2GSK3AGSK3B
SCHEMBL29536913 1.00 LRRK2 (0.42) LRRK2ABL1HDAC2GSK3AGSK3B
SCHEMBL29537782 1.00 LRRK2 (0.42) LRRK2ABL1HDAC2GSK3AGSK3B
SCHEMBL24285976 1.00 LRRK2 (0.42) LRRK2ABL1HDAC2GSK3AGSK3B
SCHEMBL29536982 1.00 LRRK2 (0.42) LRRK2ABL1HDAC2GSK3AGSK3B
SCHEMBL24286681 1.00 LRRK2 (0.42) LRRK2ABL1HDAC2GSK3AGSK3B
SCHEMBL29537630 0.93 LRRK2 (0.40) LRRK2ABL1PIK3CDEGFRHCK
SCHEMBL24285945 0.93 LRRK2 (0.40) LRRK2ABL1PIK3CDEGFRHCK
SCHEMBL24286626 0.85 LRRK2 (0.37) LRRK2ABL1HDAC2GSK3AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4214207-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1st Biotherapeutics, Inc. (KR) 2023-07-26 — — EP claimed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds 1ST Biotherapeutics, Inc. (KR) 2023-09-05 — — US disclosed
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS 1ST Biotherapeutics, Inc. (KR) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11744824-B2 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds NLRP3, NLRP1, KCNJ2 LRRK2 538/4885ABL1 966/4885HDAC2 86/4885
US-20220087985-A1 2-AMINO-3-CARBONYL IMIDAZOPYRIDINE AND PYRAZOLOPYRIDINE COMPOUNDS NLRP3, NLRP1, KCNJ2 LRRK2 538/4885ABL1 966/4885HDAC2 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback